+1 Recommend
0 collections
      • Record: found
      • Abstract: not found
      • Article: not found

      Current Progress in Electrotransfection as a Nonviral Method for Gene Delivery

      1 , 1

      Molecular Pharmaceutics

      American Chemical Society (ACS)

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          <p class="first" id="P1">Electrotransfection (ET) is a nonviral method for delivery of various types of molecules into cells both in vitro and in vivo. Close to 90 clinical trials that involve the use of ET have been performed, and approximately half of them are related to cancer treatment. Particularly, ET is an attractive technique for cancer immunogene therapy because treatment of cells with electric pulses alone can induce immune responses to solid tumors, and the responses can be further enhanced by ET of plasmid DNA (pDNA) encoding therapeutic genes. Compared to other gene delivery methods, ET has several unique advantages. It is relatively inexpensive, flexible, and safe in clinical applications, and introduces only naked pDNA into cells without the use of additional chemicals or viruses. However, the efficiency of ET is still low, partly because biological mechanisms of ET in cells remain elusive. In previous studies, it was believed that pDNA entered the cells through transient pores created by electric pulses. As a result, the technique is commonly referred to as electroporation. However, recent discoveries have suggested that endocytosis plays an important role in cellular uptake and intracellular transport of electrotransfected pDNA. This review will discuss current progresses in the study of biological mechanisms underlying ET and future directions of research in this area. Understanding the mechanisms of pDNA transport in cells is critical for the development of new strategies for improving the efficiency of gene delivery in tumors. </p><p class="first" id="P2"> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/6fd270f8-1912-4583-8b30-44874806dca4/PubMedCentral/image/nihms-983215-f0001.jpg"/> </div> </p>

          Related collections

          Author and article information

          Molecular Pharmaceutics
          Mol. Pharmaceutics
          American Chemical Society (ACS)
          July 30 2018
          September 04 2018
          June 11 2018
          September 04 2018
          : 15
          : 9
          : 3617-3624
          [1 ]Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States
          © 2018


          Comment on this article